Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c
about
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastomaCrizotinib resistance: implications for therapeutic strategiesThe role of the ALK receptor in cancer biologyTackling ALK in non-small cell lung cancer: the role of novel inhibitorsMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyCombating acquired resistance to tyrosine kinase inhibitors in lung cancerPF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsThe ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceCombined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinibAlectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHarnessing C-H Activation of Benzhydroxamates as a Macrocyclization Strategy: Synthesis of Structurally Diverse Macrocyclic Isoquinolones.P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerDiscovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung CancerThe ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNALK: a tyrosine kinase target for cancer therapy.The use of small-molecule structures to complement protein-ligand crystal structures in drug discoveryNovel ALK inhibitors in clinical use and development.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Agents in the preclinical development stage for non-small cell lung cancer.Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284.Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.ALK alterations and inhibition in lung cancer.
P2860
Q24310296-A1974693-93D9-42B3-9583-2AD9C6C05965Q26738381-61A53066-96AE-4B86-8CF7-7D6CC87A8532Q26738384-FE8CAB24-8EB9-47CA-B621-000270789C36Q26740329-92E65BC3-F9BA-4B80-9A90-9B655D3767DEQ26769659-959C4A89-E8AF-4B92-9015-60D310764071Q26769879-37FA45D1-A904-4F36-A18D-223C76557184Q26775347-420D35C9-9228-4F43-B875-4A6B7E97EB6CQ26795555-60EF5B81-A790-4A0F-AD56-C90C98CDAD75Q26824877-0DD2FA54-6BBA-4CBB-817E-3BADC085DEA0Q27853138-8B700BCB-B143-442B-9F26-3281AC85D96BQ27853241-0B523C2F-7BA4-4DC5-B0FF-0ED426C28EFAQ27853298-BF408287-54FA-4207-8A05-49BDD25F8071Q28071903-FD5277BC-49CD-4652-8F99-4263AABD1AF6Q33699808-8AD88DC1-FA2C-49FD-A8A7-BD645BD2D647Q33804619-E8020CFA-5719-4686-BB5C-4D9F4ED19B8FQ35007620-931C8E92-B768-4CF7-B840-4CF39190D0C1Q35833066-17733AE3-9F65-4EA7-B369-44C04E9019F7Q35858617-6F95FC58-D2F1-4C1D-83A3-A1DCD72DED8BQ36028073-72DAA833-94E4-4BDE-8D9A-2BBE601F55C0Q36538788-7CFF122C-8BBC-416D-A4B0-B45308B623CAQ37003600-CD9C511F-3D9C-46B3-97FA-B48B920D853AQ37017020-80B708F5-01DD-443D-92F1-1AC837409FDEQ37305906-7952B757-D6D5-4D7A-86A8-E579A8D21413Q37518624-61C2F09C-2BD5-437B-B169-61E0C8C8FA73Q37698627-0A045983-2DC4-4A44-9AEB-5DC5B533760BQ38427240-023D50FE-FBC4-449B-86D6-793CB0055825Q38484053-DF9B4579-852A-4E72-80DA-1151484CCAADQ38528130-38B324AB-73E7-4E54-BCF7-491153C22B9DQ38540135-09CA3943-103B-4D6B-B7C5-A8BC9309111DQ38576015-8FBB11E0-141E-4405-BCB6-6BE74E36A212Q38612204-F30D045E-2408-44E3-AC36-E9713B7D6718Q38616826-A924A184-6FE8-4282-8F48-8397B06D235CQ38663460-179CCDF9-7F6A-4475-8041-12F73089EAF9Q38738053-CBF40385-C5A8-4E04-9AB6-19C6339DCA2AQ38739807-B2C1E09F-4E31-4B65-9403-F5086455294BQ38759673-D86A9267-E718-436F-84A7-307B46731AF2Q38809939-54A4E206-A81E-4459-9B3C-172B8BB66BB4Q38816270-4C7147C2-4BEB-4981-863B-B8E4053842A4Q38816700-09A9218B-3C06-48A4-B595-947BC459098CQ38820412-87BE4152-AAAE-493D-8190-3A36B7DAD361
P2860
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Discovery of (10R)-7-amino-12- ...... ic lymphoma kinase (ALK) and c
@nl
type
label
Discovery of (10R)-7-amino-12- ...... ic lymphoma kinase (ALK) and c
@nl
prefLabel
Discovery of (10R)-7-amino-12- ...... ic lymphoma kinase (ALK) and c
@nl
P2093
P3181
P356
P1476
Discovery of (10R)-7-amino-12- ...... gainst ALK-resistant mutations
@en
P2093
Albert E Stewart
Alexei Brooun
Benjamin J Burke
Cynthia L Palmer
Graham L Smith
Helen Y Zou
Huichun Zhu
J Jean Cui
P304
P3181
P356
10.1021/JM500261Q
P407
P577
2014-06-12T00:00:00Z